Umeå-based biopharmaceutical company Lipum has been working towards a stock exchange listing since 2018 – and now the moment has finally arrived.
On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq’s opening bell, which has been specially transported to Umeå, to mark the occasion.
Umeå-based biopharmaceutical company Lipum AB is raising capital for a listing on the Nasdaq First North Growth Market in the spring of 2021.
“We are taking the next exciting step in the company’s development”, says Lipum’s CEO Einar Pontén.
Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO).
Now Umeå company Lipum brings more expertise to the company. Professor Anders Fasth steps in as an advisor in the development of medicines for inflammatory diseases.
“It is very gratifying that he joins the team,” says Einar Pontén, CEO of Lipum.
Life science industry figurehead Pernilla Abrahamsson has left her position as Product Development Manager at stock market listed Senzime to become Chief Operating Officer (COO) at Lipum, located at the Umeå Biotech Incubator.
Umeå life science company Lipum will participate in one of the world’s largest congresses for rheumatic diseases this June.
“The elite of our industry gathers at this congress once a year and competition is incredibly intense. It’s important to be seen there”, says Einar Pontén, CEO of Lipum.
Umeå-based Lipum, which is developing a biological drug for the treatment of chronic inflammation, has attracted SEK 25 million in new investment to help boost the company’s growth.
After a thorough selection process, Lipum AB has been granted SEK 22 million from the EU’s Horizon 2020-initiative. This is a great leap forward for researchers who want to better quality of life for children and adults with chronic inflammatory diseases.
